Abiopharma

🔍 Donovan Joanne M. (Executive)

Company: Edgewise Therapeutics, Inc. (EWTX)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 28,662 shares of Common Stock at $7.08 per share (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 38,259.00 | transaction_form_type: 4
• Sold 28,662 shares of Common Stock at $32.3109 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: false | shares_owned_after: 9,597.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 28,662 shares of Stock Option (Right to Buy) at $7.08 per share (Derivative)
  Date: 2026-04-01 | Code: M | Expires: 2033-08-17 | equity_swap_involved: false | shares_owned_after: 125,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
• F2: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.